ARTEMIDE-Gastric01: A phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC).

Authors: Rui-Hua Xu, Diogo Bugano Diniz Gomes, Jen-Shi Chen, Florian Lordick, Andrew Scott Paulson, Sun Young Rha, Josep Tabernero, Kensei Yamaguchi, Jun Zhang, Jacqui Aitchison, Zhuoer Sun, Qian Zhu, Ye Xia, Anastasia Jiang, Xia Li, Osama E. Rahma, Manish A. Shah

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4204

Source: Full article

---

Abstract

TPS4204